newsfilter
← Latest News
GlobeNewswire·

ProMIS Neurosciences' PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer's disease

TORONTO, Ontario and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as